New spin off company ONIRIA Therapeutics founded by VHIO, UB and ICREA, with the support of “la Caixa”, AECC and ISCIII, sets out to counteract cancer resistance & combat disease relapse

22_03_16_Constitucion-Oniria
  • ONIRIA’s flagship first-in-class molecule, ONR-001, has been designed and developed to block tumor growth by activating the epigenetic enzyme TET2.
  • TET2 is an orchestrator of the control and survival of dormant tumor cells. These latent cells are the long-term core of cancer persistence. When triggered to reactivate they aggressively go forth, multiply uncontrollably, and dodge anti-cancer therapies.
  • ONR-001 has demonstrated efficacy in preclinical animal models by inducing and sustaining cancer cell dormancy or even promoting tumor cell death upon prolonged treatment.
  • This pioneering approach aims to slay these sleeping, tricky-to-track, and treatment-resistant cancer cells by preventing their seeding of tumors and metastatic cell spread.

Barcelona, 24th of March 2022– The Vall d’Hebron Institute of Oncology (VHIO), Universidad de Barcelona (UB), and the ICREA Catalan Institution for Research and Advanced Studies, have joined forces and founded a new spin off, ONIRIA Therapeutics.

Funded by  “la Caixa” Foundation, Asociación Española Contra el Cáncer – AECC (Spanish Association Against Cancer), and the Instituto de Salud Carlos III – ISCIII (Institute of Health Carlos III), this biotech company is dedicated to developing targeted therapies for precision medicine in oncology. ONIRIA’s team is pioneering novel approaches aimed at modulating dormant tumor cells (DTCs), also known as slow-cycling cancer cells (SCCCs).

By modulating cell dormancy to overcome cancer persistence, this newly launched spin off strives to provide new anti-cancer armory to counteract resistance and prevent disease relapse in patients.

Among various ongoing projects, the spin off’s most advanced agent is a first-in-class molecule, ONR-001, that allosterically activates the TET2 master epigenetic enzyme, causing tumor cells to enter a dormant state and even die. TET2 is a major orchestrator of the epigenome that governs the global gene expression pattern of cancer cells, capable of sending them to sleep without sacrificing their malignant status.

ONIRIA Therapeutics has already secured patent protection for its TET2 modulators and demonstrated efficacy in preclinical animal models by showing that ONR-001 promotes and sustains cancer cell dormancy and even causes cell death upon prolonged treatment. The investigators are now evaluating the efficacy of ONR-001 in several hematologic and solid tumor types, honing in on those cancers that are hypermethylated as a consequence of TET2 loss-of-function.

Héctor G. Palmer, Principal Investigator of VHIO’s Stem Cells & Cancer Group, is ONIRIA’s Chief Scientific Officer, and Esther Riambau, an expert venture builder, serves as the company’s Chief Executive Officer. The founding team  also comprises Isabel Puig, a Senior Investigator of Héctor’s group, who is the company’s Scientific Advisor for new therapeutic targets; Xavier Barril, an ICREA investigator at UB, and ONIRIA’s Scientific Advisor in computational chemistry; Carlos Galdeano, a Serra Hunter Lecturer Professor and Head of the Protein Degradation Laboratory at UB, who is appointed as its Scientific Advisor in drug discovery; and Josep Tabernero, VHIO’s Director, Head of the Medical Oncology Department at the Vall d´Hebron University Hospital (HUVH), who is ONIRIA’s Clinical Advisor.

“While we are increasingly delivering on the true promise of precision medicine in oncology, two major challenges that hamper progress in improving outcomes for patients are resistance to therapy and disease recurrence. ONIRIA strives to combat dormant tumor cells, counteract treatment resistance and prevent the regression and progression of disease,” said Héctor G. Palmer.

 “At VHIO we are devoted to translating our research into improved clinical outcomes for the direct benefit of cancer patients. To do so, the creation of spin off companies is instrumental in developing potential new treatment avenues discovered in the laboratory, and further accelerating our drug discovery efforts,” added Josep Tabernero.

This pioneering project has been possible thanks to the support received from several institutions including the ”la Caixa” Foundation, Asociación Española Contra el Cáncer – AECC (Spanish Association Against Cancer), Instituto de Salud Carlos III – ISCIII (Institute of Health Carlos III), Agència de Gestió d’Ajuts Universitaris I de Recerca – AGUAR (Agency for Management of University and Research Grants), Fundación FERO (FERO Foundation), and the Fundació Privado CELLEX (CELLEX Private Foundation).

The paradox of dormant tumor cells

Cancer cells have acquired all the necessary alterations to grow and multiply in an uncontrolled manner. However, certain molecular mechanisms can force them to enter into a slumber.

“These dormant tumor cells can persist undetected as treatment-resistant seeds and disperse in other parts of the body in patients thought to be cured. Eventually they reactivate and grow, triggered by factors that we don’t completely understand, and behave like cancer stem cells, regenerating the original tumor,” observed Isabel Puig, a Senior Investigator of Héctor G. Palmer’s lab, and ONIRIA’s Scientific Advisor for new therapeutic targets.

Over the past few years, research directed by Héctor G. Palmer has culminated in the development and refinement of their approach to identify, isolate and analyze DTCs. His group uncovered their central role in disease relapse, and discovered that TET2 is a key factor ruling their underlying biology.

This original research*, showed TET2 to be a promising novel drug-target as a strategy to eliminate these cells, and that 5-Hydroxymethylcytosine (5hmC), generated by TET2, can be utilized as a biomarker for chemoresistant DTC detection and a predictor of worse survival.

“Most importantly, by previously exposing TET2 as the Achilles heel of DTCs, we are now pioneering novel inhibitors to block this enzyme activity toward combating treatment resistance and preventing cancer recurrence,” concluded Héctor G. Palmer.

Reference:

* Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest. 2018 Aug 31;128(9):3887-3905.